SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.37-8.4%Jan 16 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: xomadog2 who wrote (9974)5/14/1999 7:13:00 PM
From: schadenfreude  Read Replies (1) of 17367
 
>That is why among other reasons,BPI is being used in Menningococcemia
> instead of SEPSIS. The FDA still wants to do a SEPSIS trial with BPI >using mortality as the primary end point.

Assuming all goes well with meningococcemia, what additional trials will be needed for sepsis and how long will they take? If another trial is required, what was the point of wasting 3 1/2 years on a niche indication that doesn't come close to justifying the the massive investment in time and resources?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News